ALR Technologies Inc - ALRT stock
OTC Symbol: ALRT
About ALRT Stock[edit]
ALR Technologies Inc (OTC: ALRT) is a healthcare technology company based in Richmond, Virginia, USA. The company specializes in developing remote monitoring and medication adherence solutions for chronic diseases such as diabetes, hypertension, and congestive heart failure.[1]
ALR Technologies (OTC: ALRT) began trading on the OTC exchange in May 2020.[2]
Products[edit]
Health-e-Connect System[edit]
The Health-e-Connect system includes a wireless monitoring device, a mobile app, and a web portal that enable patients to monitor their vital signs, track medication usage, and receive personalized coaching from healthcare professionals. The system uses artificial intelligence and machine learning algorithms to identify trends and provide personalized recommendations to patients, which can help improve patient outcomes and reduce healthcare costs.[3]
Diabetes[edit]
In November 2020 the company announced that its diabetes solution platform had been cleared by Health Canada.[4] The company's Diabetes Solution Platform was cleared by Health Canada. The Diabetes Solution Platform is a remote monitoring system that enables patients with diabetes to monitor their blood glucose levels, track medication usage, and receive personalized coaching from healthcare professionals.[4]
The platform includes a wireless monitoring device, a mobile app, and a web portal that enable patients to upload their blood glucose readings and medication usage data to a secure cloud-based server. The data can then be accessed by healthcare professionals, who can monitor patients remotely and provide personalized coaching to help patients better manage their diabetes.[4]
The clearance from Health Canada allows ALR Technologies Inc. to market and sell the Diabetes Solution Platform in Canada. The platform has the potential to improve patient outcomes and reduce healthcare costs by helping patients with diabetes better manage their condition, reducing the risk of complications, and enabling healthcare professionals to provide more targeted and personalized care.[4]
The clearance from Health Canada is an important milestone for ALR Technologies Inc., as it allows the company to expand its reach and increase its sales revenue in the Canadian market. It also highlights the company's commitment to leveraging technology to improve the delivery of healthcare and improve patient outcomes.[4]
The ALRT device makes insulin dose suggestions using artificial intelligence and best practice guidelines. Clinical trials have shown a reduction of 1.2% in A1C over six months in the most difficult to control patients. Studies have shown that a 1% drop reduces cardiovascular risks by 45%, microvascular disease by 25%, and death by 21%.
Animal Health[edit]
In June 2021 the company announced that it had created an animal health division and will be launching a product called GluCurve Pet CGM in 2022. The product will be sold to veterinarians and will eliminate the need for a cumbersome glucose testing process.[5]
Distribution Partnership[edit]
In December 2022, ALR Technologies Inc announced a distribution partnership with a global medical supply distributor. The partnership aims to expand the distribution of ALRT's Health-e-Connect system, which is a remote monitoring solution designed to help patients with chronic conditions manage their health. ALR Technologies Inc's distribution partnership is expected to help the company expand its reach and increase its sales revenue. It also aligns with the company's mission to improve patient outcomes and reduce healthcare costs by leveraging technology to improve the delivery of care.[6]
- ↑ alrt.com. Home. Retrieved on 4/11/2023.
- ↑ alrt.com. Investors. Retrieved on 4/11/2023.
- ↑ alrt.com. Divisions. Retrieved on 4/11/2023.
- ↑ 4.0 4.1 4.2 4.3 4.4 GlobeNewswire. ALRT Diabetes Solution Platform is Cleared by Health Canada. November 23, 2020.
- ↑ alrt.com. Animal Health. Retrieved on 4/11/2023.
- ↑ NewDirect. ALR Technologies Announces Co-branded Distribution Partnership with Covetrus for GluCurve Pet CGM, the First Continuous Glucose Monitoring System for Diabetic Pets. December 01, 2022
